

Journal of Visualized Experiments

A DNA/Ki67-Based Flow Cytometry Assay for Cell Cycle Analysis of Antigen-Specific CD8 T Cells in Vaccinated Mice --Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE61867R2
Full Title:	A DNA/Ki67-Based Flow Cytometry Assay for Cell Cycle Analysis of Antigen-Specific CD8 T Cells in Vaccinated Mice
Corresponding Author:	Francesca Di Rosa Istituto di Biologia e Patologia Molecolari Consiglio Nazionale delle Ricerche Rome, ITALY
Corresponding Author's Institution:	Istituto di Biologia e Patologia Molecolari Consiglio Nazionale delle Ricerche
Corresponding Author E-Mail:	francesca.dirosa@cnr.it
Order of Authors:	Sonia Simonetti Ambra Natalini Giovanna Peruzzi Alfredo Nicosia Antonella Folgori Stefania Capone Angela Santoni Francesca Di Rosa
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Open Access (US\$4,200)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Rome, Italy
Please confirm that you have read and agree to the terms and conditions of the author license agreement that applies below:	I agree to the Author License Agreement
Please specify the section of the submitted manuscript.	Immunology and Infection
Please provide any comments to the journal here.	we up-loaded figures in pdf, but can provide the.ai format upon request

TITLE:

A DNA/Ki67-Based Flow Cytometry Assay for Cell Cycle Analysis of Antigen-Specific CD8 T Cells in Vaccinated Mice

AUTHORS AND AFFILIATIONS:

Sonia Simonetti^{1,2*}, Ambra Natalini^{1,2*}, Giovanna Peruzzi³, Alfredo Nicosia⁴, Antonella Folgori⁵, Stefania Capone⁵, Angela Santoni², Francesca Di Rosa¹

¹Institute of Molecular Biology and Pathology, National Research Council of Italy (CNR), Rome, Italy

²Department of Molecular Medicine, University of Rome "Sapienza", Rome, Italy

³Center for Life Nano Science, Istituto Italiano di Tecnologia, Rome, Italy

⁴Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy

⁵Reithera Srl, Rome, Italy

* These authors contributed equally to the work

Sonia Simonetti's current address: Medical Oncology Department, Campus Bio-Medico University, Rome, Italy

Email addresses of co-authors:

Sonia Simonetti (s.simonetti@unicampus.it)

Ambra Natalini (ambra.natalini@uniroma1.it)

Giovanna Peruzzi (giovanna.peruzzi@iit.it)

Alfredo Nicosia (alfredo.nicosia@gmail.com)

Antonella Folgori (antonella.folgori@reithera.com)

Stefania Capone (stefania.capone@reithera.com)

Angela Santoni (angela.santoni@uniroma1.it)

Corresponding Author:

Francesca Di Rosa

Email Address: francesca.dirosa@cnr.it

KEYWORDS:

antigen-specific CD8 T cells, cell cycle, Ki67, DNA dye, flow cytometry, spleen, lymph nodes, mouse.

SUMMARY:

Clonal expansion is a key feature of antigen-specific T cell response. However, the cell cycle of antigen-responding T cells has been poorly investigated, partly because of technical limitations. We describe a flow cytometric method to analyze clonally expanding antigen-specific CD8 T cells in spleen and lymph nodes of vaccinated mice.

ABSTRACT:

The cell cycle of antigen-specific T cells in vivo has been examined by using a few methods, all of which possess some limitations. Bromodeoxyuridine (BrdU) marks cells that are in or recently completed S-phase, and carboxyfluorescein succinimidyl ester (CFSE) detects daughter cells after division. However, these dyes do not allow identification of the cell cycle phase at the time of analysis. An alternative approach is to exploit Ki67, a marker that is highly expressed by cells in all phases of the cell cycle except the quiescent phase G_0 . Unfortunately, Ki67 does not allow further differentiation as it does not separate cells in S-phase that are committed to mitosis from those in G_1 that can remain in this phase, proceed into cycling, or move into G_0 .

Here, we describe a flow cytometric method for capturing a “snapshot” of T cells in different cell cycle phases in mouse secondary lymphoid organs. The method combines Ki67 and DNA staining with major histocompatibility complex (MHC)-peptide-multimer staining and an innovative gating strategy, allowing us to successfully differentiate between antigen-specific CD8 T cells in G_0 , in G_1 and in S- G_2 /M phases of the cell cycle in the spleens and draining lymph nodes of mice after vaccination with viral vectors carrying the model antigen gag of human immunodeficiency virus (HIV)-1.

Critical steps of the method were the choice of the DNA dye and the gating strategy to increase the assay sensitivity and to include highly activated/proliferating antigen-specific T cells that would have been missed by current criteria of analysis. The DNA dye, Hoechst 33342, enabled us to obtain a high-quality image of the G_0/G_1 and G_2 /M DNA peaks, while preserving membrane and intracellular staining. The method has great potential to increase knowledge about T cell response in vivo and to improve immuno-monitoring analysis.

INTRODUCTION:

Naïve T cells undergo clonal expansion and differentiation upon antigen-priming. Differentiated T cells display effector functions that are essential for antigen clearance and for the maintenance of antigen-specific memory, which is key for long-lasting protection. During the first steps of the primary response, naïve T cell interaction with antigen-presenting cells (APCs) within specialized niches in lymphoid organs is critical to induce the huge T cell proliferation that characterizes the clonal expansion phase¹⁻³. T cell-APC interaction is finely regulated by concentration and persistence of antigen, co-stimulatory signals, and soluble factors (cytokines and chemokines) that influence the quantity and quality of the T cell clonal progeny⁴⁻⁷.

Despite intensive studies of T cell clonal expansion, it is still not known whether antigen-primed T cells complete their entire cell cycle at the site of antigen recognition, or whether they migrate to other organs during cell cycle progression. This lack of knowledge is due to the availability and properties of tools used for cell cycle analysis. These include monoclonal antibodies (mAbs) specific for the nuclear marker, Ki67, and cell dyes that either identify cells that have undergone the S-phase of the cell cycle (e.g., BrdU) or discriminate among daughter cells and their ancestors (e.g., CFSE).

However, cell-labeling dyes, such as CFSE and BrdU, do not allow the determination as to

whether cells found in a particular organ proliferated locally or rather migrated to this site after division⁸⁻⁹. Moreover, the intranuclear protein, Ki67, is only able to distinguish cells in G₀ (Ki67-negative cells) from those in any other cell cycle phase (Ki67-positive cells). Thus, Ki67 analysis does not distinguish cells in active proliferation (i.e., in S, G₂, or M) from those in G₁, which may either quickly progress to division or stay for long periods in G₁ or revert to quiescence¹⁰⁻¹¹.

Here, we describe a new flow cytometric method for cell cycle analysis of antigen-specific CD8 T cells¹² from the spleen and lymph nodes (LNs) of vaccinated mice (**Figure 1**). The method exploits a combination of Ki67 and DNA staining that was previously used to analyze the cell cycle of mouse bone marrow (BM) hematopoietic cells¹³⁻¹⁴. Here, we successfully applied Ki67 plus DNA staining, together with the recently published innovative gating strategy¹², to the analysis of CD8 T cell clonal expansion. We were able to clearly discriminate between antigen-specific CD8 T cells in G₀, in G₁, and in S-G₂/M phases in the spleens and draining LNs of vaccinated mice.

PROTOCOL:

Mice were housed at Plaisant Animal Facility, and the work was performed under Italian Ministry of Health authorization number 1065/2015-PR. The protocol followed the animal care guidelines according to national and international laws and policies (UE Directive 2010/63/UE; Italian Legislative Decree 26/2014).

1. Preparation of medium and staining solution

1.1. Prepare Complete Medium: RPMI medium with 2 mM glutamine, 100 U/mL penicillin/streptomycin, 50 µM beta-mercaptoethanol, and 10% v/v fetal bovine serum (FBS)

1.2. Prepare Staining Buffer: Phosphate-buffered saline (PBS) with 1% w/v bovine serum albumin (BSA) and 2 mM ethylenediaminetetraacetic acid disodium salt solution (EDTA)

2. Mouse treatment

2.1. Prime 7–8-week-old, female Balb/c mice by intramuscular (i.m.) injection in the quadriceps of HIV-1-gag-expressing-chimpanzee adenoviral vector (ChAd3-gag) with a dose of 10⁷ viral particles.

2.2. At 1–4 months after priming, boost once the mice by i.m. injection of HIV-1-gag-expressing modified vaccinia Ankara virus (MVA-gag) with a dose of 10⁶ plaque-forming units.

2.3. At day 3 post-boost, sacrifice the boosted mice by cervical dislocation, and analyze them in parallel with untreated mice.

2.4. Harvest the LNs draining the quadriceps (iliac, popliteal, and inguinal) and the spleens from boosted and untreated mice. Furthermore, collect the BM from the two hind legs from

untreated mice, and use this BM for flow cytometer settings and as positive control for cell cycle analysis (**Figure 2**).

NOTE: Generate ChAd3-gag and MVA-gag vectors as described previously^{12,15,16,17}.

3. Isolation of draining LNs, spleen, and BM cells

3.1. Isolation of spleen and LN cells

3.1.1. Place 5 mL of complete medium in each of two 15 mL tubes, and keep them on ice, ready for collected organs.

3.1.2. Sacrifice an adult mouse by cervical dislocation.

3.1.3. Place the mouse on its back, and sterilize the skin surface with 70% v/v ethanol.

3.1.4. To collect inguinal LNs, make a ~1 cm longitudinal incision on the abdomen with scissors, and stretch the incision with the forceps.

3.1.5. Visualize inguinal LNs on the internal surface of the skin, and harvest them with the forceps. Place the inguinal LNs in one of the two 15 mL tubes prepared in step 3.1.1.

3.1.6. To collect the spleen, make a peritoneal incision with scissors and remove the spleen. After cutting the surrounding connective tissue, place the spleen into the second 15 mL tube prepared in step 3.1.1.

3.1.7. To collect iliac LNs, remove the bowels and visualize iliac LNs close to the inferior vena cava, and then collect them by using the forceps. Place the iliac LNs in the same tube containing the inguinal LNs.

NOTE: To obtain enough LN cells for staining (see section 4), it is often necessary to pool popliteal, inguinal, and iliac LNs from one mouse. These LNs are all draining the quadriceps (the site of i.m. vaccination). This protocol uses only one 15 mL tube of pooled LNs.

3.1.8. To collect popliteal LNs, grasp the skin of the hind legs and gently pull it downwards to uncover the muscles. Then, insert the forceps between the muscles under the knee joint, and collect the popliteal LNs. Place the popliteal LNs in the same tube containing inguinal and iliac LNs.

NOTE: See note after 3.1.7.

3.1.9. Place the spleen into a 70 μ m cell strainer within a 60 mm culture dish filled with 5 mL of complete medium. Using a 5 mL syringe plunger, gently mash the organ until its complete disaggregation.

177
178 3.1.10. Remove the strainer, and transfer the cell suspension to a clean 15 mL tube.
179
180 3.1.11. Add 5 mL of complete medium to the culture dish, and carefully wash the dish to ensure
181 that all cells have been recovered. Pool with the rest of the spleen cell suspension into the 15
182 mL tube.
183
184 3.1.12. For the pooled inguinal, iliac, and popliteal LNs, prepare a single cell suspension
185 following a similar procedure to that used in steps 3.1.9 to 3.1.11 for the spleen.
186
187 3.1.13. Centrifuge cells at $400 \times g$ for 10 min at 4 °C. Discard the supernatant, and resuspend
188 the cell pellets in PBS without Ca^{2+} / Mg^{2+} .
189
190 3.1.14. Count the cells with a Neubauer chamber using red blood cell lysis buffer and 0.04% v/v
191 trypan blue in PBS.
192
193 3.2. Isolation of BM cells
194
195 3.2.1. Place 5 mL complete medium in a 15 mL tube, and keep it on ice, ready for the
196 collection of hind legs.
197
198 3.2.2. Sacrifice an adult mouse by cervical dislocation.
199
200 3.2.3. Sterilize the skin-surface with 70% v/v/ ethanol (v/v).
201
202 3.2.4. Make a ~1 cm transverse incision on the ventral skin with scissors, firmly grasp the skin
203 on both sides of the cut, and gently pull downwards to uncover the muscles of the hind legs.
204
205 3.2.5. To eliminate the skin from the back of the hind legs, place the mouse in a supine
206 position, place the clamp under the knee, and pull upwards to expose the muscles.
207
208 3.2.6. Cut the bones at the two extremities of one hind leg: the pelvic/hip joint and the ankle.
209
210 3.2.7. Transfer both hind legs to the 15 mL tube prepared in step 3.2.1. Keep the tube on ice.
211
212 3.2.8. Take the hind legs from the 15 mL tube and transfer them to tissue paper. Cut the hind
213 legs just below the knee-joint to remove the tibia. Dissect the femur and tibia from the
214 surrounding muscles, remove excess tissue using scissors, and wet the tissue paper.
215
216 3.2.9. Cut the bone ends with scissors to expose the interior marrow shaft. Insert the tibia and
217 femur into the BM extraction tube (see preparation in 3.2.9.1–3.2.9.2¹⁸), with the widest end at
218 the bottom.
219
220 3.2.9.1. Cut a 200 μL pipette tip at the line just above the end of the tip and at the 100 μL

line.

3.2.9.2. Place the middle part into the upper, larger section of the tip, and place this in a 1.5 mL microfuge tube.

3.2.10. Spin the BM extraction tube at $800 \times g$ for 1 min.

3.2.11. Discard the bone, and vigorously resuspend the pellet in 1 mL of complete medium to remove any clusters. Filter the cell suspension through a $70 \mu\text{m}$ filter placed on the top of a 15 mL tube.

3.2.12. Wash the BM extraction tube twice with 1 mL of complete medium each time. Filter through a $70 \mu\text{m}$ filter, and pool the volume with the rest of the cell suspension obtained in step 3.2.11.

NOTE: A single 15 mL tube will contain cells from both hind legs of a mouse.

3.2.13. Centrifuge cells at $400 \times g$ for 10 min at 4°C . Discard the supernatant, and resuspend the cell pellet in PBS.

3.2.14. Count the cells with a Neubauer chamber using red blood cell lysis buffer and 0.04% v/v trypan blue in PBS.

4. Staining of spleen, LN, and BM cells

4.1. Divide cell samples to be stained into 3 subgroups: **cell samples for compensation**, including BM cells from untreated mice to be stained with Hoechst 33342 (henceforth referred to as Hoechst) only and spleen cells from untreated mice to be used to prepare a dead/live cell mix for dead cell dye compensation; **positive control for cell cycle analysis**, consisting of a BM sample from untreated mice; and **experimental samples** containing spleen and LN samples from untreated and vaccinated mice.

NOTE: Ensure that there are enough spleen and LN cells for analysis of sufficient numbers of gag-specific CD8 T cells. It is often necessary to use pooled spleen cells and pooled LN cells from 3 vaccinated mice and stain two or more identical samples of pooled cells, each containing 3×10^6 cells. Merge identical samples at the step of Hoechst staining. Similarly, stain pooled spleen cells and LN cells from 3 untreated mice, and merge identical samples at the end. Set aside an **unstained sample** of spleen cells from an untreated mouse to be used for instrument and compensation setup.

4.2. Prepare dead/live cell mix for dead cell dye compensation (this mix of cells will be stained only with the dead cell dye).

4.2.1. Heat a water bath at 65°C .

265
266 4.2.2. Take an aliquot of spleen cells ($\sim 3 \times 10^6$).
267

268 4.2.3. Transfer the cell suspension to a microfuge tube, place it in a water bath at 65 °C for 5
269 min, and then immediately place it on ice for 10 min.
270

271 4.2.4. Mix the heat-killed cells with live spleen cells ($\sim 3 \times 10^6$) in a ratio of 1:1, and transfer half
272 of the mixture to a 96 well-round bottom plate ($\sim 3 \times 10^6$ cells/well for the dead cell staining
273 control).
274

275 4.3. Dead cell staining of experimental samples and dead/live cell mix
276

277 4.3.1. Transfer spleen, LN, BM cells (3×10^6 cells/well), and the dead/live cell mix (section 4.2)
278 into 96-well round-bottom plate, according to the staining scheme (step 4.1), and centrifuge at
279 $400 \times g$ for 3 min at 4 °C.
280

281 4.3.2. Resuspend each cell pellet in 50 μ L of dead cell dye diluted in PBS, and resuspend by
282 pipetting up and down 3 times immediately.
283

284 4.3.3. Incubate for 30 min at 4 °C, protected from light.
285

286 4.3.4. Wash cells 2 times with staining buffer; the first time with 200 μ L and the second time
287 with 250 μ L. For each wash centrifuge the plate at $400 \times g$ for 3 min at 4 °C.
288

289 4.3.5. Discard the supernatant, and resuspend the cell pellet in 20 μ L of PBS.
290

291 4.4. Membrane cell staining with MHC-peptide multimers and mAbs.
292

293 4.4.1. Taking into account the necessary volumes according to the staining scheme, prepare
294 the following reagents:
295

296 4.4.1.1. Dilute mAb 2.4G2 in the staining buffer according to the appropriate dilution
297 (see **Table of Materials**); for each sample to be stained, use 10 μ L of this dilution.
298

299 NOTE: 2.4G2 mAb blocks non-antigen-specific binding of immunoglobulins to the Fc γ III and Fc γ II
300 receptors.
301

302 4.4.1.2. Dilute the H-2k(d) AMQMLKETI allophycocyanin (APC)-labelled tetramer (Tetr-
303 gag) in the staining buffer to obtain a final concentration of 6 μ g/mL; for each sample to be
304 stained, use 20 μ L of this dilution.
305

306 4.4.1.3. Prepare the antibody mix by diluting mAbs in the staining buffer according to the
307 appropriate dilution (see **Table of Materials**) that has been previously determined in titration
308 experiments; for each sample to be stained, use 20 μ L of this antibody mix.

NOTE: Here, anti-CD3e peridinin chlorophyll protein (PerCP-Cy5.5) (clone 145-2C11), anti-CD8a brilliant ultraviolet (BUV805) (clone 53-6.7), and anti-CD62L phycoerythrin cyanine7 (PECy7) (clone MEL-14) were used.

4.4.2. Add 10 μ L of the previously diluted 2.4G2 mAb (step 4.4.1.1), and incubate for 10 min at 4 °C, protected from light.

4.4.3. Add 20 μ L of the previously diluted Tetr-gag APC (step 4.4.1.2) and 10 μ L of H-2k(d) AMQMLKETI phycoerythrin (PE) pentamer (pent-gag). Incubate for 15 min at 4 °C, protected from light.

4.4.4. Add 20 μ L of the previously prepared antibody mix (step 4.4.1.3), and incubate 15 min at 4 °C, protected from light.

NOTE: Hence, final volume is 80 μ L per well (step 4.3.5, steps 4.4.2 to 4.4.4).

4.4.5. Wash cells with 200 μ L of staining buffer. Centrifuge at $400 \times g$ for 5 min at 4 °C.

4.4.6. Resuspend the cell pellet in 250 μ L of staining buffer, and transfer the cell suspension to 5 mL tubes. Add 1 mL of staining buffer to the tube, and centrifuge at $400 \times g$ for 5 min at 4 °C.

4.4.7. Take the aliquot of BM cells (3×10^6 cells) (see list of cell samples at the beginning of section 4) to be used to compensate the Hoechst channel (Hoechst 33342 is read with an ultraviolet laser (**Table 2**)), and transfer the cell suspension into a 5 mL tube. Add 1 mL of staining buffer to the tube, and centrifuge $400 \times g$ for 5 min at 4 °C.

5. Fixation/permeabilization

5.1. Prepare fresh fixation/permeabilization buffer by diluting 1 part of fixation/permeabilization concentrate with 3 parts of fixation/permeabilization diluent, according to the manufacturer's instructions.

5.2. Discard the supernatant and pulse vortex the samples to completely disaggregate the pellet.

5.3. Add 1 mL of fixation/permeabilization buffer to each tube and vortex.

5.4. Incubate for 16 h at 4 °C.

NOTE: The protocol can be paused here.

6. Intracellular staining

6.1. Ki67 staining

6.1.1. Prepare fresh permeabilization wash buffer 1x by diluting 10x fixation/permeabilization buffer with distilled water, according to the manufacturer's instructions. Before use, the permeabilization wash buffer must be filtered through a 0.45 μ m filter to eliminate aggregates.

6.1.2. Dilute mAb Ki67 fluorescein isothiocyanate (FITC) (clone SolA15) in 1x permeabilization wash buffer (see **Table of Materials**), as determined previously in titration experiments (final volume of 100 μ L per well).

6.1.3. Add 3 mL of 1x permeabilization wash buffer to each tube, and centrifuge at 400 $\times g$ for 5 min at room temperature (RT).

6.1.4. Discard the supernatant and repeat step 6.1.3.

6.1.5. Discard the supernatant, and resuspend the cell pellet in 100 μ L of previously diluted mAb Ki67 FITC (step 6.1.2).

6.1.6. Incubate for 30 min at RT, protected from light.

6.1.7. Wash cells 2 times with 4 mL of 1x permeabilization wash buffer. For each wash centrifuge at 400 $\times g$ for 5 min at RT.

6.1.8. Resuspend the cell pellet in PBS considering the following volumes: 350 μ L of PBS for the samples to be acquired directly at the flow cytometer; 250 μ L of PBS for the samples to be incubated with Hoechst shortly before flow cytometry (section 6.2).

6.2. DNA staining

6.2.1. Add 250 μ L of 4 μ g/mL Hoechst in PBS to each sample (final concentration of Hoechst is 2 μ g/mL).

NOTE: In case two or more identical samples of 250 μ L in PBS were prepared, merge them at this step, and add equal volume of 4 μ g/mL Hoechst solution in PBS (final concentration of Hoechst is 2 μ g/mL). The number of cells greatly influences the DNA staining step. Use the same cell number in each sample. Be aware that even a slightly reduced cell number (e.g., due to cell loss in previous washing steps) results in lower Hoechst binding to DNA and lower Hoechst intensity.

6.2.2. Incubate for 15 min at RT, protected from light.

6.2.3. Centrifuge the samples at 400 $\times g$ for 5 min at RT.

6.2.4. Resuspend the cell pellet in 350 μ L of PBS.

7. Preparation of compensation bead samples

7.1. Prepare 5 μ L of the antibody by diluting mAb in the staining buffer appropriately.

NOTE: For each fluorochrome-conjugated mAb used in the experiment, prepare its corresponding compensation bead sample.

7.2. Vortex anti-mouse Ig, κ CompBeads before use.

7.3. For each sample, introduce one drop (\sim 20 μ L) of negative control and one drop of anti-Mouse Ig, κ CompBeads in a single 5 mL tube.

7.4. Add 5 μ L of the prediluted antibody (step 7.1) to the tube, and pipet up and down.

7.5. Incubate for 15 min at 4 $^{\circ}$ C, protected from light.

7.6. Wash samples with 2 mL of staining buffer. Centrifuge at $400 \times g$ for 5 min at 4 $^{\circ}$ C.

7.7. Discard the supernatant, and resuspend the pellet by adding 500 μ L of PBS to each tube and vortex.

8. Instrument and compensation setup and experimental sample acquisition at the flow cytometer

NOTE: Refer to **Table 2** for the cytometer configuration.

8.1. General instrument and compensation setup

8.1.1. Open the software for sample acquisition (see **Table of Materials**), and create a new experiment by clicking **New Experiment** in the workspace ribbon section and selecting **New Blank Experiment**.

8.1.2. Double click on the created experiment to open it.

8.1.3. In the **Cytometer Settings** window, click on **Parameters** and select all the channels (PE, APC) used in the staining panel including Forward Scatter (FSC) and Side Scatter (SSC) parameters.

8.1.4. Select linear scale as a Hoechst parameter by unchecking the log scale, and check the Width (W) of the voltage pulse for FCS, SSC, and Hoechst.

NOTE: All the parameters are shown by default in logarithmic (log) scale, except for FSC and SSC that are in linear scale. All the parameters are analyzed by the Area (A) and the Height (H) of

the voltage pulse.

8.1.5. On the **Global Worksheet**, create a dot plot with FSC-A on the x-axis and SSC-A on the y-axis.

8.1.6. Run the unstained spleen sample by clicking **Acquire Data** on the **Acquisition Dashboard**.

8.1.7. Set the appropriate FSC and SSC settings to visualize the cells by modifying the voltage values in the **Parameters** section, and create a gate to select all the cells displayed in the FSC-A/SSC-A dot plot by clicking on **Polygon Gate** on the workspace toolbar of the **Global Worksheet**.

8.1.8 Display the gated cells in histograms with each fluorescence parameter on the x-axis.

8.1.9. Run unstained and fully stained spleen samples to adjust the fluorescence detector (PMT) to have a clear separation between negative and positive signals of the stained cells for each fluorescence parameter.

8.1.10. To perform compensation setup, click on **Experiment** in the workspace ribbon and under **Compensation Setup** section, select **Create Compensation Controls**. Uncheck **Include Unstained Control Tube/Well** and click **Ok**.

NOTE: This operation will result in the creation of a specimen named **Compensation Controls** and a **Normal Worksheet** containing several sheets corresponding to each selected parameter.

8.1.11. Run a sample of compensation beads (see section 7); set the appropriate FSC and SSC settings to visualize the beads by modifying the voltage values and the acquisition threshold of 5,000 on FSC parameters in the **Cytometer** window.

8.1.12. Adjust the P1 gate on the bead population, and check that the positive and negative peaks are both visible on the x-axis. Repeat this operation for each compensation bead sample, and finally record each sample file by clicking **Record Data** on the **Acquisition Dashboard** (record at least 5,000 events for each sample).

8.1.13. For each recorded bead sample, set the P2 and P3 gates on the positive and negative peaks, respectively.

8.1.14. Run the cell samples for compensation (see steps 4.2 and 4.4.7, and sections 5 and 6). Modify the FSC and SSC voltages and the threshold value to visualize the cells, adjust P1 gate, and finally record each sample file (record at least 10,000 events). Set the P2 and P3 gates on the positive and negative peaks, respectively.

NOTE: For the compensation of Hoechst channel, use the G₀/G₁ as the negative peak (P3) and

the G₂/M as the positive one (P2).

8.1.15. Click on **Experiment** in the workspace ribbon section and in the **Compensation Setup** section, select **Calculate Compensation**.

8.1.16. Name the created compensation setting, link, and save it to the current experiment.

8.2. Experimental sample acquisition

8.2.1. Open a specimen by clicking **New Specimen** on the browser toolbar, and create the gating strategy in the **Global Worksheet**.

NOTE: The gating strategy of sample acquisition is similar to that of sample analysis, described in **Figure 3** and section 9.

8.2.1. Display **All Event** population in a histogram with CD3-A on the x-axis. Create an **Interval Gate** to select only the CD3⁺ cells.

8.2.2. On the **Acquisition Dashboard**, select storage gate as **All Events** for LN samples and CD3⁺ cells for spleen samples.

8.2.3. Run the experimental samples at low speed, and finally record all the files making sure to collect at least 100–200 antigen-specific CD8 T cells for each sample from the vaccinated mice.

NOTE: The file size of experimental samples is usually big (30–120 MB), especially when the frequency of antigen-specific CD8 T cells is low. Hence, high numbers of events ($> 1 \times 10^6$) have to be collected to record at least 100–200 antigen-specific CD8 T cells. Big files might slow down the subsequent data analysis process. The acquisition of only CD3⁺ cells in spleen samples (see step 8.2.2 above) is helpful to keep the file size smaller.

8.2.4. Run and record the positive control for cell cycle analysis, i.e., BM sample from untreated mice.

9. Data Analysis

9.1. Open the software (see **Table of Materials**), and create different groups corresponding to the different organs to be analyzed by clicking **Create Group** in the workspace ribbon section (i.e., create group “a-spleen”; “b-LNs”; “c-BM”).

NOTE: Newly created groups will appear in the group list, while the “Compensation” group is automatically generated by the software.

9.2. Open the **Modify Group** window by double clicking on the group name, and check that

the newly created groups are synchronized. If not, insert a checkmark on the function **Synchronized**.

9.3. Drag each .fcs file in its corresponding group.

9.4. Create the gating strategy starting with “a-spleen” group.

9.5. Double click on the fully stained sample in the group to open the graph window.

9.6. Display the total events acquired for this sample in a dot plot with DNA-A on the x axis and DNA-W on the y-axis.

9.7. Select only the single cell population by clicking on **Rectangle** in the gating tool section of the graph window.

NOTE: Single cells have DNA-A values as follows: 2N (low): between 2N and 4N (intermediate), or equal to 4N (high), while DNA-W values are identical for all of them (step 1 of **Figure 3**).

9.8. Double click in the center of the rectangular gate to display single cells in a dot plot with FSC-A parameter on the x-axis and dead cell dye on the y-axis.

9.9. Select only the live cell population by clicking on **Polygon** in the gating tool section of the graph window. Live cells are negative for the dead cell dye (step 2 of **Figure 3**).

9.10. Double click in the center of the polygonal gate to display the cells in a dot plot with FSC-A parameter on the x-axis and SSC-A parameter on the y-axis.

9.11. Click on **Rectangle**, and create a “relaxed” gate to include all the single live cells in that graph¹² (step 3 of **Figure 3**).

9.12. Double click in the center of the “relaxed” gate to display the cells in a dot plot with CD3 on the x-axis and CD8 on the y-axis.

9.13. Select the CD3⁺CD8⁺ cells by clicking on **Polygon** (step 4 of **Figure 3**).

9.14. Double click in the center of the CD3⁺CD8⁺ gate to display the cells in a dot plot with Tetr-gag on the x-axis and Pent-gag on the y-axis.

9.15. Select the antigen-specific CD8 T cells (positive for both Tetr-gag and Pent-gag) by clicking on **Polygon** (step 5 of **Figure 3**).

9.16. Double click in the center of the gag-specific gate to display the cells in a dot plot with DNA-A on the x-axis and Ki67 on the y-axis (**Figure 4**).

9.17. Select the cells in the different cell cycle phases by clicking on **Quad** in the gating tool section of the graph window.

NOTE: Cell in G_0 phase are Ki67neg-DNA low cells (bottom left quadrant); cells in G_1 are Ki67pos-DNA low (upper left quadrant); cells in S- G_2 /M are Ki67pos-DNA intermediate/high (top right quadrant) (**Figure 4**).

9.18. Copy the gating strategy created in one sample to the corresponding group to apply the gates to all the samples of the group.

9.19. Repeat steps 9.5 to 9.18 for the “b-LN group”.

9.20. For the “c-BM” group, repeat steps 9.5 to 9.11 (**Figure 2A**). To analyze the cell cycle among the BM cells, click in the center of the “relaxed” gate to display the cells in a dot plot with DNA-A on the x-axis and Ki67 on the y-axis, and select the cells in the different cell cycle phases (see step 9.17).

9.21. Check that all the gates are appropriate for the 3 groups (i.e., for cells from spleen, LN, and BM).

NOTE: Single cell population gate (step 9.7) and Quad gate for cell cycle (step 9.17) may have different gate coordinates in different samples, mainly due to the possible slight differences of the Hoechst dye intensity between samples (section 6.2). For this reason, it might be necessary to modify the Single cell population gate and the Quad gates for cell cycle in each sample. This will be done as follows: double click on the group name, and remove the synchronization from the group properties. This operation allows the modification of the gates in one sample without modifying the same gates in all the other samples of the group. After synchronization removal, modify the gates where necessary.

9.22. To visualize the results obtained by this analysis, click on **Layout Editor** in the workspace ribbon section to open it. Drag each gate of the gating strategy in the sample pane to the layout editor, and place the plots according to the sequence of the gating strategy.

9.23. Click on the **Group** and **iterate by** functions on the layout ribbon to visualize the results obtained in each organ, and compare different samples.

REPRESENTATIVE RESULTS:

The cell cycle phases of cells from spleen, LNs, and BM of Balb/c mice were analyzed using the fluorescent DNA dye, Hoechst, and an anti-Ki67 mAb, according to the protocol summarized in **Figure 1**. This staining allowed the differentiation of cells in the following phases of cell cycle: G_0 (Ki67neg, with 2N of DNA defined as DNA_{low}), G_1 (Ki67pos, DNA_{low}), and S- G_2 /M (Ki67pos, with a DNA content comprised between 2N and 4N, or equal to 4N of DNA defined as DNA_{intermediate/high}).

We first performed cell cycle analysis of BM cells to reproduce previously published results¹³⁻¹⁴ and then analyzed the cells of interest, i.e., CD8 T cells. **Figure 2** shows a typical example of cell cycle analysis of BM cells (**Figure 2A**). The protocol yielded a low coefficient of variation (CV) of G₀/G₁ and G₂/M DNA peaks, indicating the excellent quality of the DNA staining (**Figure 2B**, showing an example with CV < 2.5; CV was always < 5 in all the experiments).

We then applied the same protocol to antigen-specific CD8 T cells from vaccinated mice. BALB/c mice were vaccinated against the antigen gag of HIV-1 by using Chad3-gag for priming and MVA-gag for boosting, both engineered to carry HIV-1 gag. At day (d) 3 post-boost, we analyzed the frequency of gag-specific CD8 T cells from the spleen and draining LNs. We took advantage of the newly defined gating strategy for T cells in the early phase of immune response, which in contrast to the conventional strategy, is appropriate for detecting antigen-responding CD8 T cells¹². We executed the novel strategy in five subsequent steps. In step 1, we excluded doublets or aggregates by DNA-A/ -W gate, and in step 2, we identified live cells by dead cell marker exclusion. In step 3, we identified the population of interest using a non-conventional “relaxed” FSC-A/ SSC-A gate (**Figure 3A**) instead of the canonical narrow lymphocyte gate¹². After gating on CD3⁺CD8⁺ cells (step 4 of **Figure 3A**), we identified gag-specific CD8 T cells by using two different MHC multimers, i.e., Pent-gag and Tetr-gag (step 5 of **Figure 3A**). We used two multimers instead of one to improve the sensitivity of gag-specific CD8 T cell detection in vaccinated mice, without increasing the staining background in untreated mice (**Figure 3B**, step 5). Thus, we successfully distinguished untreated mice (0.00% and 0.00% antigen-specific CD8 T cells in LNs and spleen, respectively) from vaccinated mice (0.46% and 0.29% antigen-specific CD8 T cells in LNs and spleen, respectively).

Notably, the protocol allowed us to have an extremely low background in the antigen-specific CD8 T cell gate of LNs and spleens of untreated mice (usually 0.00% and at maximum 0.02%). The overlay of gag-specific CD8 T cells onto total CD8 T cells in the FSC-A / SSC-A plot showed that the gag-specific cells had high SSC-A and FSC-A (**Figure 3C**), confirming the need to use a “relaxed” FSC-A/ SSC-A gating to capture these cells. We then evaluated the percentages of gag-specific CD8 T cells in different cell cycle phases (**Figure 4A**). We found that gag-specific CD8 T cells in the spleen and even more in the draining LNs contained a high proportion of cells in S-G₂/M phase at day 3 post-boost (18.60% and 33.52%, respectively).

Furthermore, we found that gag-specific CD8 T cells in S-G₂/M phase had high FSC-A and SSC-A, when overlaid onto the total CD8 T cells from the same organ (**Figure 4B**). CD62L expression by gag-specific CD8 T cells was low, as expected for activated T cells, except for a few cells in G₀ in the LNs (**Figure 4C**). Altogether, these results confirmed that the “relaxed” gate (step 3 of **Figure 3**) was required to include all of the proliferating antigen-specific CD8 T cells¹². The protocol was extremely valuable for a “snapshot” evaluation of cell cycle phases of antigen-specific CD8 T cells at the time of analysis and of CD62L expression by cells in different cell cycle phases.

FIGURE AND TABLE LEGENDS:

Figure 1: Scheme of the protocol for cell cycle analysis of antigen-specific CD8 T cells.

Figure 2: Cell cycle analysis of BM cells. BM cells from untreated Balb/c mice were stained and analyzed by flow cytometry. **(A)** Example of gating strategy. We gated on single cells in the DNA-A/-W plot (left) and subsequently on live cells by dead cell dye exclusion (middle). Then, a “relaxed” FSC-A/SSC-A gate was used for all BM cells (right). **(B)** Example of cell cycle analysis of BM cells (left). We used a combination of Ki67 and DNA staining to identify cells in the following phases of cell cycle: G_0 (bottom left quadrant, Ki67neg-DNA_{low} cells), G_1 (top left quadrant, Ki67pos-DNA_{low}), S- G_2 /M (top right quadrant, Ki67pos-DNA_{intermediate/high}). Fluorescence Minus One (FMO) control of Ki67 mAb (middle) and DNA histogram (right) are shown. In the DNA histogram plot, the left and right gates correspond to the G_0/G_1 and the G_2 /M DNA peak, respectively, and the numbers represent the coefficients of variation (CV) of each peak. In all the other plots, the numbers represent cell percentages in the indicated gates. The figure shows 1 representative experiment out of 5. In each experiment, we analyzed pooled BM cells from 3 mice.

Figure 3: Analysis of antigen-specific CD8 T cells from LNs and spleen. Balb/c mice were primed intramuscularly (i.m.) with Chad3-gag and boosted i.m. with MVA-gag. At day 3 post-boost, draining LNs and spleen cells from vaccinated and untreated control mice were stained and analyzed by flow cytometry. **(A)** Scheme of the gating strategy in five steps to identify single cells (Step 1); live cells (Step 2); lymphocytes (Step 3); CD8 T cells (Step 4); and gag-specific cells (Step 5). **(B–C)** Example of plots: analysis of cells from **(B)** LNs and **(C)** spleens of untreated (top) and vaccinated (bottom) mice. We identified single cells on the DNA-A/-W plot in Step 1. Then, in Step 2, we selected live cells by dead cell dye exclusion. In Step 3, we used a non-canonical “relaxed” gate for lymphocytes. In Step 4, we identified CD8 T cells by their double expression of CD3 and CD8. We then identified gag-specific cells and not gag-specific in Step 5, based on their capacity to bind fluorochrome-labelled H-2kd-gag-Pentamer (Pent-gag) and H-2kd-gag-Tetramer (Tetr-gag), or not, respectively. **(D)** FSC-A/SSC-A profiles of gag-specific (blue) and not gag-specific (grey) cells after gating as described above. Numbers represent cell percentages in the indicated gates. The figure shows 1 representative experiment out of 5. In each experiment, we analyzed pooled spleen and pooled LN cells from 3 vaccinated mice and 3 untreated mice.

Figure 4: Cell cycle analysis of antigen-specific CD8 T cells. Mice were vaccinated as in **Figure 3** and cell cycle analysis of gag-specific cells was performed at day 3 post-boost, after gating in 5 steps as in **Figure 3**. **(A)** Example of cell cycle analysis of gag-specific CD8 T cells from LNs (top) and spleen (bottom) of vaccinated mice. Cell cycle phases were identified as in **Figure 2B**. The panels represent cells in G_0 , in G_1 , and in S- G_2 /M (left) and Fluorescence Minus One (FMO) control of Ki67 mAb (right). Numbers represent cell percentages in the indicated gates. **(B)** FSC-A/SSC-A dot plots showing gag-specific CD8 T cells in S- G_2 /M phase (in red) overlaid onto total CD3⁺CD8⁺ T cells (in grey) from LNs (top) and spleen (bottom) of vaccinated mice. **(C)** Offset histograms showing CD62L expression by gag-specific CD8 T cells in G_0 (green), in G_1 (blue), and in S- G_2 /M (red) from LNs (top) and spleens (bottom) of vaccinated mice. The y-axes indicate normalized number of events. The figure shows 1 representative example out of 5 independent

experiments with a total of 15 mice.

Supplementary Material: Flow cytometer settings.

DISCUSSION:

Although T cell clonal expansion has been intensively studied, some aspects remain unknown, mostly because the tools available to investigate it are few and have their own drawbacks. From this perspective, we set up a highly sensitive flow cytometric method to analyze cell cycle of antigen-specific CD8 T cells at early times after vaccination in a mouse model. The protocol is based on a combination of Ki67 and DNA staining, which was previously used to analyze the cell cycle of BM hematopoietic cells in mice¹³⁻¹⁴. To adapt the protocol to antigen-specific CD8 T cells, we had to consider a few critical issues, including the choice of the DNA dye, the appropriate conditions to obtain comparable DNA staining across different samples, and the gating strategy for data analysis.

Many dyes are available for DNA staining, including propidium iodide and 7-aminoactinomycin D; we chose Hoechst because it was compatible with membrane staining and the mild fixation / permeabilization protocol required for Ki67 staining. At the same time, staining with Hoechst allowed us to obtain a DNA histogram of excellent quality, i.e., the G₀/G₁ and G₂/M DNA peaks had a much lower coefficient of variation (CV) than DNA peaks usually obtained with other DNA dyes, e.g., DRAQ5¹⁹. Indeed, Hoechst can stain DNA even in live cells²⁰.

Some strategies were used to avoid the fluctuation in Hoechst intensity in different samples of the same experiment. Hoechst staining was performed just before sample acquisition at the flow cytometer to minimize the decline of dye intensity during time. For those interested in reproducing the protocol in big experiments with numerous samples, we recommend performing Hoechst staining on a few samples at a time. One other drawback is that Hoechst intensity can be heavily influenced by cell number during incubation with the dye. For this reason, we strongly recommend always using the same number of cells and the same volume per sample for DNA staining. If a high number of cells is required for acquisition at the flow cytometer, we recommend preparing two or more identical samples and then merging them just before the Hoechst staining step.

A key point of the protocol is the gating strategy for data analysis. We recently published a novel strategy for T cell analysis at early times of the immune response, which allowed us to increase the sensitivity of detection of antigen-specific T cells¹². We applied this strategy to the data shown here as follows. First, we excluded cell aggregates in the DNA-A/W plot. Second, after gating out dead cells, we used a fairly large lymphocyte gate in the FSC/SSC plot ("relaxed gate"). By this strategy, we were able to include highly activated antigen-specific CD8 T cells in S-G₂/M that are usually missed by current gating strategies, as these cells have high FSC-A and SSC-A. In summary, the data analysis represents a critical part of the method, which is essential to obtain a sensitive detection of activated /proliferating antigen-specific T cells.

The method prevents the possibility of missing critical T cell data at early phases of immune

response and opens new perspectives for T cell immuno-monitoring. A future improvement might be to include staining for phospho-histone 3 that would allow differentiation between G₂ and M²¹. A current limitation is that cells have to be fixed and permeabilized to stain for the nuclear marker, Ki67. Thus, cells cannot be used for other types of analysis such as sorting and subsequent functional or genomic analysis. Moreover, DNA dyes, including Hoechst, usually interfere with the genomic analysis and are not suitable for this type of evaluation. Identification of membrane markers that correlate with different cell cycle phases and that can be stained on live cells could overcome this limitation. In conclusion, the method has great potential for the evaluation of activated/proliferating T cells in several contexts such as vaccination, infection, immuno-mediated diseases, and immuno-therapy.

ACKNOWLEDGMENTS:

This work was supported by Reithera, by MIUR project 2017K55HLC_006, and by 5 × 1000 grant from Associazione Italiana Ricerca sul Cancro (AIRC).

DISCLOSURES:

A. Folgori and S. Capone are employees of Reithera Srl. A. Nicosia is named inventor on patent application WO 2005071093 (A3) “Chimpanzee adenovirus vaccine carriers.” The other authors have nothing to disclose.

REFERENCES:

1. Castellino, F. et al. Chemokines enhance immunity by guiding naive CD8⁺ T cells to sites of CD4⁺ T cell- dendritic cell interaction. *Nature*. **440** (7086), 890–895 (2006).
2. Zhang N., Bevan M. J. CD8(+) T cells: foot soldiers of the immune system. *Immunity*. **35** (2), 161–168 (2011).
3. Bajénoff, M. et al. Highways, byways and breadcrumbs: directing lymphocyte traffic in the lymph node. *Trends Immunology*. **28** (8), 346–352 (2007).
4. Bevan, M. J., Fink, P. J. The CD8 response on autopilot. *Nature Immunology*. **2** (5), 381–382 (2001).
5. Van Stipdonk, M. J., Lemmens, E. E., Schoenberger, S. P. Naïve CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. *Nature Immunology*. **2** (5), 423–429 (2001).
6. Kaech, S. M., Wherry, E. J., Ahmed, R. Effector and memory T-cell differentiation: implications for vaccine development. *Nature Review Immunology*. **2** (4), 251–262 (2002).
7. Beverley, P.C. Primer: making sense of T-cell memory. *Nature Clinical Practice Rheumatology*. **4** (1), 43–49 (2008).
8. Parretta, E. et al. CD8 cell division maintaining cytotoxic memory occurs predominantly in the bone marrow. *Journal of Immunology*. **174** (12), 7654–7664, 2005.
9. Di Rosa, F. Maintenance of memory T cells in the bone marrow: survival or homeostatic proliferation? *Nature Review Immunology*. **16** (4), 271 (2016).
10. Di Rosa, F. Two niches in the bone marrow: a hypothesis on life-long T cell memory. *Trends in Immunology*. **37** (8), 503–512 (2016).

- 791 11. Di Rosa, F. Commentary: Memory CD8(+) T cells colocalize with IL-7(+) stromal cells in
792 bone marrow and rest in terms of proliferation and transcription. *Frontiers in Immunology*. **7**,
793 102 (2016).
- 794 12. Simonetti, S. et al. Antigen-specific CD8 T cells in cell cycle circulate in the blood after
795 vaccination. *Scandinavian Journal of Immunology*. **89** (2), e12735 (2019).
- 796 13. Wilson A. et al. c-Myc controls the balance between hematopoietic stem cell self-
797 renewal and differentiation. *Genes & Development*. **18** (22), 2747–2763 (2004).
- 798 14. Hirche, C. et al. Systemic virus infections differentially modulate cell cycle state and
799 functionality of long-term hematopoietic stem cells in vivo. *Cell Report*. **19** (11), 2345–2356
800 (2017).
- 801 15. Colloca, S. et al. Vaccine vectors derived from a large collection of simian adenoviruses
802 induce potent cellular immunity across multiple species. *Science Translational Medicine*. **4**
803 (115), 115ra2 (2012).
- 804 16. Di Lullo, G. et al. Marker gene swapping facilitates recombinant Modified Vaccinia Virus
805 Ankara production by host-range selection. *Journal of Virological Methods*. **156** (1–2), 37–43
806 (2009).
- 807 17. Di Lullo, G. et al. The combination of marker gene swapping and fluorescence-activated
808 cell sorting improves the efficiency of recombinant modified vaccinia virus Ankara vaccine
809 production for human use. *Journal of Virological Methods*. **163** (2), 195–204 (2010).
- 810 18. <https://www.mousephenotype.org/data/secondaryproject/3i>
- 811 19. Yoon, H., Kim, T. S., Braciale, T. J., The cell cycle time of CD8+ T cells responding in vivo is
812 controlled by the type of antigenic stimulus. *PLoS One*. **5** (11), e15423, 2010.
- 813 20. Pauklin, S., Vallier, L. The cell-cycle state of stem cells determines cell fate propensity.
814 *Cell*. **155** (1), 135–147 (2013). Erratum in: *Cell*. **156** (6), 1338 (2014).
- 815 21. Vignon, C. et al. Flow cytometric quantification of all phases of the cell cycle and
816 apoptosis in a two-color fluorescence plot. *PLoS One*. **8** (7): e68425 (2013).
- 817

DAY 0

- **Isolation of lymph nodes-(LN), spleen and bone marrow (BM) from untreated and vaccinated mice**
- **Staining of spleen, LN and BM cells**
 - Dead cell staining
 - Cell membrane staining with fluorochrome-conjugated mAbs
 - Cell membrane staining with fluorochrome-conjugated MHC-peptide multimers
- **Fixation/Permeabilization**



DAY 1

- **Intracellular staining**
 - Ki67 staining
 - DNA staining with Hoechst 33342
- **Preparation of compensation bead samples**
- **Instrument and compensation setup, and sample acquisition at the flow cytometer**
- **Data analysis**




A**B**

Figure 3


A




[Click here to access/download:Figure:61867_R1_Fig3.pdf](#)

B

LN
Untreated




LN
Vaccinated




C

Spleen
Untreated




Spleen
Vaccinated




D

LN
Vaccinated




not gag-specific




Spleen
Vaccinated

gag-specific





not gag-specific





[Click here to access/download;Figure;61867_R1-Fig4.pdf](#) 


LNs




Spleen




B



SSC-A



C



Name of Material/Equipment

15 ml conical tubes
 2.4G2 anti-FcγR mAb

 2k(d) AMQMLKETI allophycocyanin (APC)-labelled tetramer
 5 ml syringe plunger
 60 mm TC-treated Cell Culture Dish
 70 μm cell strainer
 96-well Clear Round Bottom TC-treated Culture Microplate

 Anti-Rat/Hamster Ig, k/Negative Control Compensation Particles
 Beta-mercaptoethanol
 Bovine Serum Albumin
 BUV805 Rat Anti-Mouse CD8a

 Dulbecco's Phosphate Buffer Saline w/o Calcium w/o Magnesium
 eBioscience Foxp3 / Transcription Factor Staining Buffer Set
 Eppendorf Safe-Lock Tubes, 1.5 mL
 Ethanol

 Ethylenediaminetetraacetic Acid Disodium Salt solution (EDTA)
 Fetal Bovine Serum
 Filcon, Sterile, Syringe-Type 70 μm
 Fixable Viability Dye eFluor 780
 Foxp3 / Transcription Factor Staining Buffer Set
 H-2k(d) AMQMLKETI phycoerythrin (PE) labelled pentamer
 Hoechst 33342, Trihydrochloride, Trihydrate - 10 mg/mL Solution in Water
 Ki-67 Monoclonal Antibody (SolA15), FITC
 L-Glutamine 100X (200 mM)
 Millex-HA Filters 0.45 μm
 Penicillin/Streptomycin 100X
 PE/Cyanine7 anti-mouse CD62L Antibody
 PerCP-Cy5.5 Hamster Anti-Mouse CD3e
 Red Blood Cell Lysis Buffer
 Round-Bottom Polystyrene Tubes, 5 mL
 RPMI 1640 Medium without L-Glutamine with Phenol Red
 Software package for analyzing flow cytometry data
 Software for acquisition of samples at flowcytometer
 TipOne 200 μl Tip
 Trypan Blue Solution

Company	Catalog Number	Comments/Description
Merck Millipore	SBHA025SB	
BD	553141	10 µg/ml final concentrati
provided by NIH Tetramer Core Facility		
BD Emerald	307733	
Falcon	353002	
Falcon	352097	
Falcon	353077	
BD- Bioscience	552845	
Sigma	M3148	
Sigma	A07030	
BD- Bioscience	564920	4 µg/ml final concentratic
Euroclone	ECB4004L	
eBioscience	00-5523-00	
Eppendorf	30120159	
Sigma	34852-1L-M	
Sigma	E7889	
Corning	35-079-CV	
Falcon	352350	
eBioscience	65-0865-14	1:1000 final concentration
eBioscience	00-5523-00	
Proimmune	F176-2A-E - 176	
ThermoFisher	H3570	
eBioscience	11-5698-82	5 µg/ml final concentratic
Euroclone	ECB3000D	
BD	340606	
Euroclone	ECB3001D	
Biologend	104418	0.2 µg/ml final concentra
BD- Bioscience	551163	4.4 µg/ml final concentra
Sigma	R7757	
Falcon	352058	
Euroclone	ECB9006L	
FlowJo	v.10	
BD FACSDiva	v 6.2	
StarLab	S1111-0800	
Euroclone	ECM0990D	

ion

in

n

in

tion
tion

Dear Editor
The Journal of Visualized Experiments

I should like to submit to *The Journal of Visualized Experiments* a second revised version of the manuscript **JoVE61867** entitled:

“A DNA/Ki67-based flow cytometry assay for cell cycle analysis of antigen-specific CD8 T cells in vaccinated mice”
by Simonetti S, Natalini A et al.

We thank the Editor for his comment and modified the text in agreement with it. The manuscript has now 3 pages that are highlighted for videography.

We also edited a few sentences, to improve the clarity of the text.
All the changes are in red in the text of our second revised manuscript file.
Please note that in the revised version we added some additional information on antibody concentrations in the table of materials, and slightly revised figure 1 to make it clearer.

All authors concur with submission. The manuscript is not currently under consideration elsewhere.

Kind regards

Francesca Di Rosa
Institute of Molecular Biology and Pathology
Italian National Research Council (CNR)
% Sapienza University, Department of Molecular Medicine
viale Regina Elena 291, 00161 Rome
phone +39 06 49255124, fax +39 06 44340632, e-mail francesca.dirosa@cnr.it

Instrument	BD LSR Fortessa								
Laser	Blue 488nm		Red 639nm			UV 355nm		Yellow/green 561nm	
Bandpass Filters	530/30	710/50	670/14	730/45	780/60	530/30	820/60	585/15	780/60
Longpass Filters	505LP	685LP		690LP	750LP	505LP	770LP		750LP
Fluorochromes/Dye used	FITC	PERCPCY5.5	APC	AF700	eFluor 780	Hoechst 33342	BUV805	PE	PECY7